TRIP13改变了线粒体功能,并促进了多发性髓瘤中博特佐米布的耐药性
Yang Chen1, Yule Liu2, Yuan Wang3
1Department of Geriatrics, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Scientific reports
|December 6, 2025
概括
甲状腺激素受体相互作用因子13 (TRIP13) 通过维护线粒体完整性,促进多发性骨髓瘤 (MM) 进展和博特佐米布 (BTZ) 耐药性. 针对TRIP13可能提供一种新的策略,以克服MM患者的BTZ耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 博尔特佐米布 (BTZ) 耐药性是多发性骨髓瘤 (MM) 治疗的一个重大障碍.
- 了解BTZ耐药性的机制对于开发有效疗法至关重要.
研究的目的:
- 调查甲状腺激素受体交互体13 (TRIP13) 在MM进展中的作用.
- 确定TRIP13在MM中BTZ耐药性的参与.
主要方法:
- 对公共数据集和临床骨髓样本的分析.
- 使用TRIP13过度表达的MM细胞系 (TRIP13-OE) 的体外研究.
- 功能测试,定量聚合酶链反应 (qPCR),共免疫沉和免疫光标签.
主要成果:
- 在MM中,TRIP13是上调调的,与晚期和低生存率相关.
- TRIP13-OE增强了MM细胞的增殖,减少了BTZ诱导的亡,并减轻了细胞循环停止.
- 在BTZ压力下,TRIP13-OE保留了线粒体功能 (膜潜力,水平,ATP产生).
- TRIP13与线粒体单载体 (MCU) 相互作用,这表明它在线粒体调节中的作用.
结论:
- TRIP13在MM进展和BTZ耐药性方面发挥着重要作用.
- 在蛋白质毒性压力下,TRIP13调节线粒体完整性,有助于抵抗.
- 针对 TRIP13 提出了一种潜在的新疗法策略,用于克服MM中BTZ抵抗.
相关概念视频
02:23Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
01:10Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
01:46Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
01:45Destabilization of Microtubules
3.4K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.4K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
01:15Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K